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Abstract 
Peripheral intravenous catheters (PIVC) are used in high volume in acute and ambulatory 
settings. Due to high volume of use in patient care, complications from a PIVC can 
significantly impact patient experience. Literature indicates complications such as blood 
exposure, phlebitis, unplanned removal, infiltration, occlusion, dwell time, pain, and cost 
have serious consequences in patient care, leading to potential delays in treatment, patient 
discomfort, patient dissatisfaction, safety concerns, nursing interruptions, increased length of 
stay, and added costs. Gap analysis indicates additional research can prove beneficial for 
evidence-based care improvement. The authors propose using the plan, do, study, act to 
conduct a feasibility study of a multi-center, randomized-controlled trial (RCT), evaluating 
three different PIVC systems to compare outcomes.  The purpose of this pilot was to 
determine the feasibility of assessing nurse and patient outcomes related to the use of 
three different types of PIVC, and to pilot implementation of a RCT prior to the 
expansion of the study to other facilities, which comparatively evaluated outcomes 
between two closed PIVC systems and an open PIVC system.  
Keywords: intravenous catheter, randomized control trial, intravenous complications, 









On June 16, 2015, a 238-bed community hospital in the mid-Atlantic state 
changed products for peripheral intravenous catheters (PIVC) and began using the system 
product for the purpose of standardization of both product and practice. This facility was 
using a PIVC for over 20 years; an all in one closed-system device.  The standardized 
product for the hospital system was an open-system device.   
The Quality and Patient Safety Department (QPS) at the pilot site began receiving 
staff event reports and patient comment cards related to the new PIVC (G. Yost, personal 
communication, June 18, 2015).  Patient comment cards were available in all outpatient 
areas as well as main lobbies throughout the hospital.  Inpatient hospital consumer 
perception of providers and systems comments were submitted by patients.  The majority 
of the submitted patient comment cards were from outpatient locations, including the 
Cancer Center, Treatment Center, and Outpatient Surgery units.  Patients with 
reoccurring visits to these units shared their experience with the new PIVC compared to 
their experience with the previous product.  The comments were reviewed and several of 
the themes that emerged from patients were:  painful insertions, pain during dwell time, 
blood leakage (during insertion), multiple insertion attempts, and frequent PIVC 
replacement.  Staff also began expressing concerns.  The top immediate concerns 
reported by staff included blood exposure risk, multiple insertion attempts, and painful 
insertion reports from patients.  Other staff concerns included kinking catheters, sheared 
catheter tips, tubing disconnects, leaking sites, PIVCs falling out, and continued pain 
during PIVC dwell time.  There had been one needle-stick and one staff mucocutaneous 
blood exposure reported by Occupational Health related to the new catheters, compared 
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to no previously reported needle-sticks or exposures related to the previous PIVC, in the 
previous year (G. Yost, personal communication, June 18, 2015).  By December 2015, the 
QPS department had received a total of 551 reported issues and 102 patient comment 
cards related to the PIVC product change.  
In response to the feedback on the new product requiring additional sticks to 
obtain PIVC access, a data analysis of the mean number of PIVC insertion attempts was 
conducted.  This provided establishment of a quantitative metric to evaluate.  The data 
source was the electronic health record (EHR), PIVC insertion attempts, and 
documentation for PIVC therapy.  Data included Emergency Department (ED), Cancer 
Center, Treatment Center, and inpatient patients.  A retrospective data review of PIVC 
attempts from the timeframe of April 13 – June 15, 2015 was compared to the post-
change timeframe of July 29 – September 30, 2015.  Six weeks of data was purposely 
removed during the timeframe of June 16 – July 28, 2015 to account for the expected 
learning curve with the new product.  Figure 1. displays the pre-mean and post-mean data 
of PIVC insertion attempts.   
A two-sample t-test concluded that the mean PIVC attempts for the new PIVC 
was statistically significantly greater than the mean PIVC attempts of the previous PIVC 
with a p-value of <0.001.  A two-sample standard deviation test concluded that the 
standard deviation of PIVC attempts for the new product was statistically significantly 
greater than the standard deviation of PIVC attempts of the previous product (closed 
PIVC system 1) with a p-value of <0.001.  A two-sample % defective test with a defect 
defined as a PIVC attempt >1 concluded that the number of defects for the new product 
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was statistically significantly greater than the number of defects for the previous product 
with a p-value of <0.001.   
Figure 1.  Mean PIVC attempts by month. 
After evaluating the influx of comment cards reporting reduced patient and staff 
satisfaction, as well as evaluating the increased number of attempts required with the new 
PIVC, continued reporting of opportunities for improvement (OFI) reports occurred; even 
though, standard onsite training occurred.  When OFI reports initially began, the facility 
immediately reached out to the other hospitals within their health system; however, no 
other hospitals were reporting similar events.  Additionally, their patient comments did 
not reflect any dissatisfaction with the standardized PIVC a PIVC system the other eleven 
hospitals had been using for greater than 20 years.  Senior Leadership then authorized 
additional training and coaching on insertion technique, which was conducted over two 
weeks, to evaluate whether problems reported and dissatisfaction were related to user 
error versus the PIVC itself.  A representative from the vendor returned onsite in the fall 
of 2015 to initiate re-training and re-education for nurses, specifically on procedure and 
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technique. Safety reports and dissatisfaction continued to be reported.  While numbers of 
nursing complaints began to drop, patient complaints continued (G.Yost, personal 
communication, July 29, 2016).  
Cost was an additional concern. A detailed cost analysis was performed by the 
QPS Department, comparing the total cost of the previous closed-system versus the 
current open-system.  The cost of the previous PIVC system included a closed system 
with the added option of a power-injectable product for PIVC situations in which a larger 
gauge is necessary for high flow.  Twelve months of usage data for both previous 
products was obtained.  Usage data for the new open-system was evaluated during the 
timeframe of August 2015 – November 2015, purposely excluding usage data during the 
first 2 months of start-up.  Add on extension sets and clave usage was included in the 
analysis for both systems to account for the increase in add-on device expense with the 
use of the open-system without a built in extension set.  An average daily cost for add-
ons was calculated by taking the total number of add-on items and dividing by the total 
cost of add-on items for the above timeframes.  The PIVC dressing usage and cost was 
included for both systems due to a change of product and increase in cost for the current 
system relative to the need for a more advanced securement dressing for the open-system.  
The cost and usage of an absorbent towel was included in the cost of the current system.  
This was an added product to the PIVC start kit due to blood leakage with an open-
system.  All usage and cost data were obtained from the materials management 
department and was rate adjusted to account for patient days.  The daily usage and cost 
for each product were multiplied for a per day cost.  The cost per day was extrapolated 
into a per month and a per year cost.  The cost per year of the current open-system was 
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calculated at $573,262.  The per year cost of the previous closed-system was calculated at 
$469,963.  Inpatient census and outpatient encounters were evaluated and compared for 
both system timeframes to eliminate concerns of increased usage due to patient volume.  
The estimated 3% increase in patient volume could produce at most a $14,000 cost 
variance.  This leaves an estimated $89,000 increase in the current open-system (G. Yost, 
personal communication, June 18, 2015).  The analysis shows that the new open-system 
is more costly than the closed-system and that comparing the cost of only the PIVC fails 
to produce an accurate evaluation of total cost incurred when switching from a closed to 
an open system.  The increase in cost can be primarily attributed to the increase in usage 
of add-on products along with the more advanced securement dressing and the added 
absorbent towel.  Other indirect costs for analysis were excluded, such as bed linens, 
towels, gauze, scrubs, etc.  Additionally, nursing time was excluded from this calculation, 
which, as indicated by an increased number of insertion attempts related to the new PIVC 
system, would also be increased.  In conclusion, there are additional costs with the open-
system some of which are not accounted for in this analysis. 
Review of Literature 
As issues remained in the clinical setting and re-training was completed, nurse 
leaders turned to the literature for further perspectives and guidance on types of PIVCs.   
A literature review was completed to establish the current available research related to 
open verses closed PIVCs and a table of evidence was compiled (Appendix I).  Three 
randomized controlled trials (RCT) were available for review, indicating a need for 
continued research in this area of interest.  A 2013 RCT with the aim to compare closed-
system with open-system PIVCs, showed an increase in dwell time, a 29% decrease in 
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phlebitis rates and a 20% relative risk reduction of catheter-related infections with a 
closed-system (González López et al., 2013).  A 2014 RCT compared an integrated 
closed-system with a built in stabilization platform to a conventional catheter with a 
blood control valve.  This study concluded that there were significantly fewer catheter 
replacements due to catheter related complications in the integrated closed-system and 
that the pre-attached wing-shaped stabilization platform was the main contributor to this 
result (Tamura et al., 2014).  The results from this study also suggested that longer dwell 
times offset the higher initial catheter costs of a closed-system.  Bausone-Gazda, 
Lefaiver, & Walters (2010), conducted a RCT at a level one trauma, American Nurses 
Credentialing Center (ANCC) Magnet® designated, facility comparing a closed-system 
with a built in stabilization platform to an open-system catheter in which an add-on 
stabilization device was applied.  This study concluded that the risk of securement related 
complications was reduced by 26% in the closed-system with the built in stabilization 
device, and findings were utilized to support the Infusion Nursing Standards of Practice 
for catheter stabilization (Bausone-Gazda, Lefaiver, & Walters, 2010).  All three studies 
found evidence of benefit by utilizing a closed versus open PIVC system.   
Blood exposure risk was a prominent concern for clinical staff and these concerns 
continued past the six week learning time period. Even after additional on-site PIVC 
insertion training, staff continued to report inability to occlude the vessel and prevent 
blood leakage during insertion for certain patients.  A 2011 quantitative study focused on 
reducing blood exposure risk and cost associated with PIVC insertion (Richardson & 
Kaufman, 2011).  In this study, when surveyed about traditional open-system PIVCs, 
49% of nurses reported blood exposure 50% of the time; 20% stated they experienced 
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blood leakage 100% of the time; 10% stated they never experienced blood leakage 
(Richardson & Kaufman, 2011).  Comparatively, nurses reported blood exposure 11% of 
the time with closed-system PIVCs (Richardson & Kaufman, 2011).  In this same study, 
when asked about blood leakage onto scrubs, 50% of nurses who had blood leak onto 
their scrubs stated that they changed immediately; the other 50% attempted to clean up 
the blood from their scrubs. This study also highlighted research related to under 
reporting of blood exposure, stating in the United States, researchers have found this rate 
to be as high as 82% (Richardson & Kaufman, 2011).    
Purpose Statement 
The purpose of this pilot was to determine the feasibility of assessing nurse and 
patient outcomes related to the use of three different types of PIVC, and to pilot 
implementation of a RCT prior to the expansion of the study to other facilities, which 
comparatively evaluated outcomes between two closed PIVC systems, and an open 
peripheral intravenous system. The open PIVC system was the current standard of care at 
the pilot facility. The rationale for including the two closed PIVC systems in this study 
was that pilot facility had been using closed PIVC system 1 for over 20 years with no 
significant patient complaints or poor patient outcomes as described previously.  It was 
also important to include a second closed PIVC system in the study.  Closed PIVC 
system 2is the second generation to the closed PIVC system 1 and it has added power 
injectable capability, meaning it is able to support high-pressure injections up to 300psi; a 
requirement for injection of dye for computerized axial tomography (CAT) scans.  The 
Shared Governance Council was involved in the decision and the council recommended 
that the closed PIVC system 2 be evaluated for effectiveness as well.   
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Variables studied were PIVC dwell time, blood exposure at insertion, 
effectiveness of insertion (flashback visualization, number of attempts), pain, needle-stick 
prevention feature, complications (phlebitis, dislodgment, infiltration, unintended 
removal), cost (device, add-on’s and other applicable materials including clean up 
supplies), nurse satisfaction and patient satisfaction. 
Problem Statement 
PIVCs are used at a high volume in both the acute and ambulatory settings 
throughout acute care facilities.  Due to the high volume of use and significance in patient 
care, failure and/or complications from a PIVC can have a significant impact.  Quality 
improvement analysis, along with the literature review, indicated that complications such 
as infiltration, leaking, pain, phlebitis, reinsertions can have serious consequences in 
patient care, leading to potential delays in treatment, patient discomfort, patient 
dissatisfaction, safety concerns, nursing interruptions, increased length of stay, morbidity, 
and added costs (Bausone-Gazda, Leaiver, & Walters, 2010; Rickard et al., 2015).  In a 
2015 abstract for a three year RCT underway at a multi-center facility, the primary 
investigator (PI) explains that if PIVC failure rates can be reduced by 10%, this could 
prevent more than 30 million failures and reinsertions in the United States alone which 
would result in reductions in cost, nursing time, and improved patient experiences 
(Rickard et al., 2015).  Additional research in this area can prove beneficial for evidence-
based care improvement within the larger healthcare system, comprised of 11 other 
hospitals, and across the nation.  Researchers are proposing to conduct a pilot of multi-
center RCT to evaluate 3 different PIVCs with the purpose of comparing complications, 
blood exposure, nurse and patient satisfaction and potential cost implications.  In order to 
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evaluate feasibility of such a study, evaluation of specific process measures was 
necessary.   
Objectives and Aims 
 The purpose of this pilot was to determine the feasibility of assessing nurse and 
patient outcomes related to the use of three different types of PIVC, and to pilot 
implementation of a RCT prior to the expansion of the study to other facilities, which 
comparatively evaluated outcomes between the closed PIVC system 1 and closed PIVC 
system 2,, and the open PIVC system. The results of this pilot have informed the 
expansion of this study to a RCT multi-site design.  Both process and outcome variables 
were collected in this pilot study.  In relation to process, the following variables were 
studied: response rates, percentage of completed questionnaires, missing data elements, 
Clinician Training, feedback from clinician training, enrollment participation, and 
preliminary costs.   The specific aims were as follows: 
1. To examine feasibility of measuring the following items listed, by measuring the: 
a.  Clinician and Patient Questionnaire response rate 
b. Percentage of Clinician and Patient Questionnaires that are complete 
b. Number of missing data elements for each study variable (i.e. number of 
data elements missing from electronic chart documentation and items on 
questionnaires) 
2. Describe clinician training completion by the number of completed Clinician 
Training Forms 
3. Describe themes in clinician evaluative comments about study training 
4. Describe themes in patient comments about PIVC insertion 
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5. Describe enrollment participation by measuring the percent of patients declining 
to provide consent 
6.  Describe preliminary costs by calculating the number of products used at the time 
of insertion multiplied by product cost. 
Guiding Framework (Theoretical Model) 
 Utilizing the Institute for Healthcare Improvement (IHI) (2016) test of change 
model, the plan, do, study, act cycle (PDSA cycle), a process evaluation was completed 
as part of the feasibility of the larger RCT study (Appendix J).  The PDSA cycle is a tool 
and model used to direct quality improvement measures.  The PDSA is a framework used 
to plan improvements, test the change, study results, and act on findings (IHI, 2016).  
Quality improvement (QI) and process evaluation are important to the RCT due to few 
publications and limited knowledge of variables being studied.  Appendix H depicts the 
research conceptual model for the larger RCT. The PDSA model allowed for iterations to 
process as needed, as the RCT expanded to other sites, building on lessons learned from 
the feasibility study at the pilot study site.  Using the PDSA cycle as part of the feasibility 
to the RCT study identified process specific problems (Bowen et al., 2009).    
During the planning phase, a workgroup with representation from all RCT 
facilities, alongside the research team, began meeting to discuss the development of the 
study, including design, study variables, and outcomes.  This group continued to meet 
weekly to develop education, communication, and clarify details of the project.  
Implementing the feasibility study site was the second phase of the PDSA cycle, where 
feasibility study outcomes (clinician and patient questionnaire response rate and 
percentage of complete questionnaires, number of missing data elements and completed 
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clinician training forms, thematic feedback from clinicians and patients, enrollment 
participation, and preliminary costs) were collected for evaluation and analysis. Analysis 
of these process measure outcomes helped guide expanding this study to the remaining 
study facilities, which was the third phase of the PDSA cycle.  Finally, evaluating the 
findings and making adjustments to any processes within the study, as indicated, was the 
last step of the PDSA cycle.   
Specific areas of process measure evaluation evaluated were acceptability (to 
what extent the process was appropriate), demand (to what extent the process was used), 
implementation (to what extent the process was delivered to participants), and practicality 
(to what extent this process was being carried out) (Bowen et al., 2009).  After IRB 
approval and initiation of the project, data collected at the pilot study site was analyzed 
and studied, and used to refine processes that were expanded upon at the other RCT 
facilities.  
Methods (Project and Study Design) 
Setting & Resources 
 Using the PDSA cycle, process measures were evaluated, culminating in an 
experimental randomized controlled clinical trial (RCT).  A 238-bed community hospital 
served as the pilot facility, with the first four weeks of the RCT comprising the data 
collection period for this pilot.  A PIVC workgroup met weekly and was comprised of 
representatives from Quality, Risk & Legal, Nursing, Performance Improvement, Process 
Improvement, Data Analytics, and IV Therapy.  The PDSA do and study phases of the 
change cycle included four-week data collection period that began after completion of 
clinician training at the pilot facility.  Three PIVCs were studied, with the comparison 
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group being the open PIVC system.  The intervention groups were the closed PIVC 
system 1 with the open PIVC system and closed PIVC system 2 with the open PIVC 
system.  
Study Population 
 Participants were selected on a convenience basis from the inpatient and 
outpatient population based on the eligibility inclusion and exclusion criteria listed in 
Table 1. The number of enrolled patients after four weeks of data collection served as the 
pilot study population.  The goal was to collect a total of 120 patients (40 enrolled 
patients for each PIVC) by the end of four weeks.  
Table 1. Inclusion and Exclusion Criteria.  
Inclusion Criteria Exclusion Criteria 
  Inpatients or Outpatients ≥ 18 years old 
 Participating in another study or previously 
participated in this current study 
 Available insertion site on the 
hand/forearm 
 Demonstrates cooperation with medical 
devices and/or treatments 
 Speaks and reads English 
 New PIVC site will be placed below an old 
infusion site or at an area of flexion 
 Able to give Informed Consent 
  Has a documented or known sensitivity to 
medical adhesive products 
 
  Has dermatitis, burns, lesions, or tattoos at 
or near the insertion site 
 
 Diaphoretic at the time of catheter 
insertion 
  Requires application of topical antibiotics 
or ointments under dressing 
 
  Has an IV site that requires a gauze pad or 
a tackifier 
 
  Is pregnant 
 Requires a 14 or 16 gauge PIVC 
 
 
 Has a condition that in the opinion of the 
investigator or staff nurse would make the 
patient unsuitable for enrollment in this 
study 
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Once a patient was deemed eligible for participation, trained personnel in 
obtaining informed consent approached him or her to invite participation.  After informed 
consent was obtained, participants were enrolled in the study.  Participants were enrolled 
Monday thru Friday, during the hours of 0800 to 1630.  Patients were enrolled during 
these hours due to additional resources being available to assist with obtaining consent as 
well as administrative tasks, such as returning study documents to the PI.   
Randomization 
A convenience sample of patients was used. After patients were identified as 
eligible for the study and informed consent obtained, the patient was randomly assigned 
to one of the three PIVCs.  The participants study group were determined randomly using 
a six-sided dice from within the convenience sample of participants.  Immediately after 
obtaining consent, the PIVC inserting clinician rolled the dice to determine random 
assignment.  If the dice rolled a ‘1’ or a ‘2’, the patient received the open PIVC system 1.  
If the dice rolled a ‘3’ or a ‘4’, the patient received the open PIVC system 2.  If the dice 
rolled a ‘5’ or a ‘6’, the patient received the closed PIVC system.  
Insertion & Maintenance Procedures 
PIVCs were inserted and maintained in accordance with guidelines from the 
Infusion Nurses Society (INS) (2016) and the Centers for Disease Control and Prevention 
(CDC, 2011).  Clinicians inserting the study PIVC were trained and competencies 
verified for inserting and maintaining each of the three types of PIVCs.  Figure 2. 
displays the enrollment and PIVC insertion process and was included as part of the 
clinician training. 
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Figure 2.  Clinician workflow for patient enrollment in PIVC Nursing Research Study. 
Clinical Training & Education of Participating Staff 
 Clinician training on the insertion technique for each device was provided in 
addition to two weeks of practice in the clinical units/setting for each device (3 weeks 
total) before beginning service as an inserting clinician.  Training was provided at no cost 
to the clinician (i.e., was scheduled during work hours with coverage for the time the 
nurse spent away from the unit).  The PI of the RCT was granted two awards, a $5,000 
Research Fellowship and $2,000 Research Scholarship, which were to be utilized to 
cover study expenses.  The Chief Nurse Executive (CNE) approved the cost of clinician 
training, and costs were absorbed by the monetary awards.  To assist the individual units, 
the internal scholarship money was available to assist with costs related to study supplies, 
so that, products and supplies were not additional costs to units. Topics included in 
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clinician training were adverse event reporting, PIVC insertion policy, consent process, 
inclusion/exclusion criteria, PIVC data collection instruments, and hands-on return 
demonstration training.  Clinicians completed demographic information and were signed 
off on review of policies, research design, and return demonstration for each of the 
above-mentioned topics.  Clinicians participating in the study were paid for their time, 
and clinicians eligible for the hospital’s recognition program received nursing research 
participatory points towards their clinical ladder portfolio. 
 Clinicians with experience and advanced skill, with regards to PIVC insertion, 
were recruited from each of the study units (ED, Cancer Center, Treatment Center, and 
Inpatient Nursing Units) and were invited to participate in the pilot study.  Clinicians 
were defined as registered nurses (RNs) or unlicensed ED Technicians and were required 
to work a minimum of 20 hours per week.  Enrollment was limited to day-time hours; 
therefore, in order to enroll patients routinely, clinicians were required to work the day-
shift and work a minimum number of hours.  
Data Collection 
Data was collected using paper questionnaires (see Appendix E and F) along with 
data extraction from the EHR.  Patient and Clinician Demographics that were collected 
are listed in Table 2.  Items collected using paper questionnaire are marked (P) and from 
the EHR are marked (E).  Clinician demographics were collected during the training 
sessions for the nurses.  All patient identifiers were removed from the database by the PI 
for de-identification purposes before conducting analyses.  A patient label was placed on 
the consent form with a corresponding participant identification (ID) code.  Thereafter, 
only the participant ID code was used to label data collection tools.  The list of patient 
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identifier and corresponding ID codes was kept in a password protected excel spreadsheet 
accessible only to the PI.  The number of patients who refused consent was tracked for 
reporting purposes only.   
Table 2. Patient and Clinician Demographics 
Patient Demographics Clinician Demographics 
 Hospital Status (i.e. Outpatient vs. 
Inpatient) (E) 
 Working Area (Unit/Department) (P) 
 Age (E)  Years of IV Insertion Experience (P) 
 MR# (E)  IV Team Member - Yes/No? (P) 
 Encounter # (E)  RN, LPN, Tech (P) 
 Gender (E)  
 Admitting Dx (E)  
 Principal Dx (E)  
 Secondary Dx's (E) (grouped by Dx 
categories) 
 
 Location (department) of insertion (P)  
  
Variables from the larger RCT were monitored for complete documentation in the 
feasibility study, and included blood leakage during insertion, effectiveness of insertion 
(number of attempts), complications (phlebitis, unplanned removal of PIVC, infiltration, 
occlusion), dwell time, pain unrelated to above variables, pain during insertion, removal 
reason, and cost will be collected electronically through the EHR.  Variables collected 
electronically (from EHR, represented by “E” in Table 2.) and observed for 
completeness, included the following: blood leakage on insertion, insertion attempts, 
complications (phlebitis, unplanned removal of PIVC, infiltration, occlusion), dwell time, 
and removal reason.  Variables collected manually (on paper, represented by “P” in Table 
2.) and observed for completeness, included the following: insertion attempts, pain 
unrelated to variables and pain during insertion, and cost.  Appendix B depicts each 
variable, its definition, and method of data collection (P) or (E).  Missing data related to 
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the above mentioned variables were evaluated by the PI and research team.  Problems 
identified with the completed documentation were discussed at the PIVC workgroup and 
solutions were developed and communicated by the PI and research team.  Any 
recommended changes were discussed and considered for process adjustments.   
 Three PIVC products were used: the open PIVC system (18-24 gauge), and closed 
PIVC system 1 and 2 (18-24 gauge).  Potential add-ons used is shown in Table 3.  
Table 3. Add On Products 
Add-On Item #  Description 
187006 7"Pressure Infusion Ext Set 
178699 Microbore Extension Set- 7 inch Non-DEHP 
179277 Microclave Clear 
 
The clinician questionnaire (completed after PIVC insertion) (Appendix F) and 
the patient questionnaire (completed after PIVC removal) (Appendix E) were collected 
by and monitored by the PI for response rate and percentage of completed forms.  These 
questionnaires were created by adapting measures from the Emergency Care Research 
Institute (ECRI), the CDC, and consulting content experts, including staff nurses and 
quality and safety nurses.  While no reliability and validity data exist for these measures, 
two nurse experts verified the content validity.  
Data Analysis 
Outcomes collected for this pilot were clinician and patient questionnaire 
response rate and percentage of completed questionnaires, number of missing data 
elements and completed clinician training forms, thematic feedback from clinicians and 
patients, enrollment participation, and preliminary costs.  After data was collected from 
secure boxes on inserting units, data was entered into an excel file and verified.  Paper 
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questionnaires were labeled with the participant’s unique participant ID code (not the 
patient’s medical record number label) for tracking purposes and collected in a secure 
lock box on each unit.  Paper questionnaire data was transcribed and coded into an excel 
file managed by and accessible only to the PI and specified members of the research 
team.  To reduce missing documents and data, the PI reviewed the enrolled participants 
EHR documentation and the questionnaires daily and made efforts to collect missing 
elements 
 EHR variables were extracted from the EHR for analysis using an internal 
reporting system called Clarity Reporting.  Data was deidentified by removing medical 
record and encounter numbers prior to aggregation and analysis.  Frequencies, descriptive 
statistics, incidence rates, and skewed data was analyzed.  Analysis that revealed findings 
that suggested making a change to the study process were discussed and considered for 
process adjustments.  Understanding process related problems improved implementation 
and expansion of this study at the other facilities.  Any solutions, recommended changes, 
or major structural problems requiring process change, affecting the IRB protocol itself, 
necessitated obtaining appropriate permissions for IRB amendment approval, and were 
updated through all appropriate IRBs. 
Human Subjects Protection 
IRB approval was obtained and patients were provided information explaining the 
study.  Consent was required and was obtained (Appendix C).  Consent was provided by 
onsite, trained personnel.  While in the study, participants were at very low risk for 
problems and were at no more risk than patients declining to participate in the study but 
whom have a PIVC inserted.  Any questions regarding participation in the study were 
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answered prior to obtaining consent.  If a patient declined to participate in the study, they 
continued to receive standard PIVC care.  All excel files were kept on a secure, 
encrypted, password protected server accessible only to the PI.  All protected health 
information was maintained in strict confidence as required by law.  
Results 
Descriptive Analysis 
 Summaries of quantitative descriptive results are described in Table 4.  Sixteen 
(n=16) clinicians were trained for this pilot, which included inserting (n=9) and 
consenting (n=7) roles.  There was some overlap of roles, as some inserting clinicians 
were also able to provide consent.  Participant enrollment (n=35) over four weeks was 
much lower than anticipated.  Anticipated enrollment was to enroll 40 participants per 
PIVC for a total enrollment of 120 participants.  All participants that were agreeable to 
participate in the study completed the consenting process.  One subject declined to 
participate after signing the consent form.  There were a total of four (n=45) 
complications during the pilot.  Complications seen during the pilot included 
unsuccessful insertion (n=1) and unplanned reinsertion (n=3).   
Questionnaires were evaluated for percent returned (response rate) and percent 
completed (missing data) as shown in Table 5.  One challenge was unreturned patient 
questionnaires (n=10), the highest contributing source of missing questionnaires. Of the 
35 patient questionnaires distributed 10 (29%) were not returned.  Of the patient 
questionnaires returned, 100% were entirely complete with all questions answered.  The 
opposite problem occurred with clinician questionnaires. Clinician questionnaire 
response rate was 100%; however, several returned questionnaires were incomplete.  
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Table 6. displays the missing clinician and patient data from both the paper questionnaire 
(1%) and the EHR data (4%).   
Table 4. Quantitative Descriptive Results 
 (n)    (%) 
 
Clinician Training (Total Clinicians 16) 16 - 
     Inserting  9 56% 
     Consenting 7 44% 
 
Enrollment (Total Insertions 35) 35 - 
Closed PIVC system 1 9 26% 
     Closed PIVC system 2 19 54% 
     Open PIVC system 7 20% 
 
Complications (Total Insertions 35) 4 11.4% 
     Unsuccessful Insertion 1 2.8% 
     Unplanned Reinsertion 3 8.6% 
 
 
Table 5. Questionnaire Response Rate 
 
 
 (n) (%) 
Clinicians 35/35 100% 
Patients 25/35 71% 
 
 
Table 6. Missing Data 
Number Missing/Total (%) 
Missing Data - Clinicians   
     Paper Questionnaire   
          Did blood leak out of the catheter during or after 
insertion? 2/35 5.7% 
          Patient will go home with PIVC inserted? 2/35 5.7% 
     EHR    
          Missing PIVC Study Type – not present in EHR 6/35 17.1% 
 
Missing Data - Patients 0 0% 
     While the PIVC was in place, what was your average pain  
level at the site of the PIVC? 0 0% 
     What was your overall level of satisfaction with the PIVC? 0 0% 
 




 Qualitative feedback was obtained through patient and clinician questionnaires.  
These forms were collected by the PI and entered into an excel spreadsheet.  Using 
Graneheim & Lundman’s (2004) content analysis approach, feedback was broken down 
into the simplest like-comments (meaning unit), which was then condensed and turned 
into a code (p. 106-107).  These codes were then grouped into similar categories as seen 
in Table 7.  The categories were reviewed and grouped into common themes, which 
included closed PIVC system 1 Experience, closed PIVC system 2 Experience, open 
PIVC system Experience, Enrollment, and Clinician Role.  These themes were less useful 
at identifying potential outcomes, but they were used to provide a framework for future 
qualitative content analysis as the study progresses (Graneheim & Lundman, 2004; Hsieh 
& Shannon, 2005). 
PIVC Experience 
 Feedback for closed PIVC system 1included “more comfortable; placement is 
more comfortable” (n=3).  Participants enrolled appeared to prefer this PIVC (n=2), and 
participants indicated it hurt less (n=4).  Top closed PIVC system 2 feedback included 
participants reporting easier insertion (n=6), less pain (n=6), and “more secure, least 
complicated” in relation to device design (n=6).  However, participants did indicate that 
the closed PIVC system 2 required restart or reinsertion (n=6).  Participants commenting 
on the open PIVC system indicated that they observed bleeding (n=4), more pain (n=2), 
and reinsertion needed (n=4).  Reports indicating that open PIVC system was their least 
favorite was also reported (n=3). 
Enrollment 
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 The majority of the feedback from clinicians indicated that they experienced the 
most difficulty in the pilot during the consenting process (n=9).  Clinicians reported that 
many patients declined to participate at the time of consent or that patients were 
agreeable until the consent form was presented.  Some clinicians reported other difficulty 
during the consent process with participants feeling overwhelmed, fearful to sign, or 
electing to not read the consent.  Clinicians also reported insufficient numbers (n=7), 
mostly with difficulty in recruiting appropriate participants that met inclusion/exclusion 
criteria and that they found it difficult to complete the required paperwork. 
Clinician Role 
 Patient feedback was overwhelmingly positive with regards to the staff working 
with them during their treatment.  Patients noted their positive feedback on staff 
knowledge (n=12).  Patients reported that “nurse medical advice has saved me pain and 
discomfort” and that “nurses work to provide best care possible”.  Staff reported that 
staffing issues (n=6) such as time off, departmental changes, and job transitions affected 
the clinician role in this pilot.  Staff also felt that clinicians should be able to insert and 
consent (n=5) to help with the staff availability issues causing delay in the consent 
process (n=4).  There was very little qualitative feedback from clinician training forms 
evaluating the initial training sessions.  As this was a pilot study, there were few 
expectations about training and participating in the study.  Clinicians provided no helpful 
evaluative feedback on training sessions; rather, they focused their comments by 
providing feedback in the clinician questionnaire.   
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Table 7. Content Analysis-Clinician and Participant Enrollment Feedback 
Themes Categories 
Closed PIVC system 1 Insertion 5 
Hurts Less 4 
Comfort 3 
Device Design 3 
Prefers PIVC 2 
Closed PIVC system 2 Reinsertion 6 
Hurts Less 6 
Device Design 6 
Easy Insertion 6 
More Comfortable 2 
Prefers PIVC 2 
Difficult Insertion 1 
Does not Prefer 1 
Easier to Move 1 
Difficult to Move 1 
Open PIVC system Bleeding 4 
Reinsertion 4 
Does not Prefer 3 
Hurts More 2 
Prefers PIVC 1 
No Bleeding 1 
Enrollment Difficulty During Consent 9 
Insufficient Numbers 7 
Clinician Role Staff Knowledge 12 
Staffing Issues 6 
Clinician Training 5 
Staff Availability 4 
Staff Professionalism 2 
 
Cost Analysis 
After initiating this pilot, two significant operational events occurred.  The first 
relates to the renegotiation of cost for the standard practice PIVC used, which led to a 
reduction in cost of about $0.15 per product.  A second operational event to occur was to 
PIVC Start Kits.  Each PIVC start kit had the surgical towel removed from the kit, 
decreasing the cost by about $0.30 per product.  The surgical towel had been previously 
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used to help with the blood leakage reported on insertion.  The surgical towel was 
replaced by a lower quality, cheaper product.  While these changes are minor, they 
contribute to an overall reduction in cost and made analyzing cost between the three 
PIVCs more difficult.  These changes occurred after presentation to the Nurse Executive 
Council in December 2015, but before beginning analysis of this pilot.  Table 8. describes 
what cost would have been if products costs would have remained steady throughout the 
pilot.  Product costs used in Table 7 are based on original figures provided by Materials 
Management at the pilot site.  Individual product costs were multiplied by products used 
in the pilot to calculate total cost.  Reinsertion costs were calculated based on a reported 
unplanned removal of the study PIVC, and totaled the sum of a standard PIVC insertion 
cost.  Cost assumptions cannot be made using the pilot results; however, the framework 
for calculating total and reinsertion costs were used to inform the larger RCT. 
Table 8. Cost Analysis – Summary of pilot costs and products used 
By Individual Product Total Cost (USD) 
     Add ons 
          7” Pressure Infusion Extension Set ($1.85/product) 
          Microbore Extension Set – 7in Non-DEHP ($1.20/product) 





     PIVC 
          Closed PIVC system 1 ($2.53/product) 
          Closed PIVC system 2 ($3.69/product) 





     Start Kit $44.10 
By PIVC Insertion 
(Total cost of insertion, including Add-ons, PIVC, and Start Kit) 
 
Closed PIVC system 1 Insertion $41.31 
     Closed PIVC system 1 Insertion $125.61 
     Open PIVC system Insertion $37.93 
By Reinsertion Costs  
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     Closed PIVC system 1 Insertion $4.64 
     Closed PIVC system 2 Insertion $9.28 
     Open PIVC system Insertion $0.00 
 
Implications 
Resource Allocation  
The largest insight this pilot revealed was the slower than expected enrollment.  
Availability of inserting and consenting clinicians was part of the issue with slow 
enrollment.  It was anticipated that the ED would enroll the most participants, and for this 
reason more inserting clinicians were trained in the ED than on inpatient units.  However, 
due to staffing changes and workflow barriers, the ED was unable to enroll any during 
this pilot.  The workflow in the ED prohibited the completion of additional consent form 
and questionnaires, a barrier to enrollment.  A future recommendation would be to 
engage nursing leadership at the unit-level earlier in the designing phases to understand 
unit-level concerns and resource allocation.  The availability of consenting clinicians also 
delayed the workflow for inserting clinicians.  Ensuring at least two consenting clinicians 
per participating unit would help reduce the waiting time for enrollment.  In addition to 
training more inserting clinicians, encouraging inserting clinicians to take human subjects 
in research training to be able to consent should be considered for the expansion of this 
study. 
Missing Questionnaires 
Missing patient questionnaires contributed to the largest category of missing 
questionnaires.  After speaking with bedside nursing, their knowledge of the pilot study 
was limited.  It was realized that communication to those participating in the study as 
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well as organization leadership had occurred, but limited information was provided to 
non-inserting and non-consenting front-line staff.  Therefore, the importance of returning 
the patient questionnaire was not communicated from shift to shift, and as a result not 
returned to the PI.  The PI established weekly rounding to reinforce the importance of 
returning patient questionnaires.  After enrollment of a participant, the consenting 
clinician was also instructed to give verbal handoff to that subject’s nurse, also 
reinforcing the importance of returning the patient questionnaire.  To make the patient 
questionnaire more visible in the room, the PI instructed participating clinicians to utilize 
the whiteboard and magnets already present in the room.  This kept the questionnaire 
visible to both the enrollee and nursing staff. 
Missing Data 
EHR data contributed as the largest source of missing data.  After drilling down 
on the missing EHR data two things were determined regarding documentation.  The first 
was that staff were not documenting the PIVC in the PIVC Study Type flowsheet.  The 
clarity report was built to pull based on the presence of data in this field for all identified 
inserting clinicians.  When this field was left blank, no information would flow into the 
clarity report, resulting in the need for manual abstraction.  The second thing identified 
was that even when this field had correct documentation present, if the inserting clinician 
was not the one to document, no information would flow into the clarity report.  It came 
to the team’s attention that clinicians not identified as an inserting clinician for the study 
would assist the inserting clinicians by documenting for them.  The clarity report was 
built to pull information documented by the inserting clinicians in the study only.  
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Education and awareness was quickly provided to the staff and participating clinicians on 
the importance of accurate documentation by inserting clinicians only.    
Informing the Larger RCT 
 The results from this pilot have informed and provided recommended changes to 
the larger RCT and are summarized in Table 9.  Understanding the workflow, process, 
and needed resources has revealed clearer expectations for the continuation and 
expansion of the study.  After analyzing the pace of enrollment and resources needed, 
recommendations for additional inpatient clinicians to be trained in both insertion and 
consenting was identified.  Strategically placing consenting clinicians will be important 
for ease of enrollment.  Furthermore, recognizing the unit-level resource limitations will 
help to identify appropriate enrollment locations.    Lastly, the work done to establish a 
framework for future content analysis was developed as a result of this pilot.   







 Second training arranged to engage more clinicians 





 Utilize patient room whiteboards and magnets to increase returned 
documents 





 Framework for future Content Analysis was developed 
 Avoid areas where consent process may delay care 
 Engage with leadership in planning phase to help with communication 
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Strengths and Limitations 
 This pilot used the PDSA cycle as the guiding framework for study 
implementation.  Using this process was a practical way of determining the feasibility of 
such a large study design in the context of a complex organizational structure.  The study 
design for the larger RCT is the first of its kind; therefore, this pilot has positively 
informed the continuation and expansion of the larger RCT.  The lessons learned and 
analysis from this pilot provides a framework for future data analysis.   
 This pilot was limited to four weeks of data collection, which may not have been 
enough time to truly understand all of the barriers and processes needing improvement.  
With a slower than expected enrollment rate and low participation from units involved, a 
longer time period for the pilot may have been beneficial.  Another limitation to this pilot 
is the shifting and renegotiation of prices for products used within the study.  Obtaining 
pricing information, along with renegotiated cost/product across the healthcare system, 
has caused considerable difficulty in completing a cost analysis.   
Conclusion 
 The pilot of a RCT comparing outcomes of three different PIVCs was 
successfully completed and has constructively informed the larger RCT.  The PDSA 
cycle is an effective guiding framework to understand the process for implementing the 
larger RCT study design.  The steps in the PDSA cycle provided structure to the PI to 
plan, implement, analyze, and act upon the proposed study.  The pilot results suggest that 
enrollment to this study is slow due to limited availability of consenting clinicians and 
that resource allocation, in general, is a barrier to this study.  Enrollment is not feasible in 
areas where workflow is time sensitive and pace of work cannot accommodate a delay in 
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patient care.  While results from this pilot were limited to identification of process 
improvement opportunities, the results of this pilot suggest that there is need for 
continued enrollment, because it is still unclear which PIVC is best in terms of 
complications, satisfaction, and cost.  The recommendation from this pilot study will be 
to continue enrollment at the pilot site and to expand to the other proposed hospitals, 
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Appendix A – Add on Products 
Table 3. Add on Products 
Add-On Item # Description 
187006 7"Pressure Infusion Ext Set 
178699 Microbore Extension Set- 7 inch Non-DEHP 
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Per INS Standards of Practice (2016), adds on are defined as devices that 
minimize manipulation and reduce multiple components, such as single and 
multi-lumen extension sets and/or needleless connectors (INS, 2016).  Add-
ons should be considered only for clinical indications (INS, 2016). 
Used at time of 
insertion. 
Adverse Event 
According to the Sentara Healthcare (SHC) Incident and Event Reporting 
Risk Management Policy, any event unrelated to the ordinary course of the 







As defined by the pilot facility’s IRB, Serious Adverse Events include any 
experience that is fatal or life threatening, is permanently or significantly 
disabling, requires inpatient hospitalization or prolongation of 
hospitalization, a congenital anomaly/birth defect or is medically 
significant.  Adverse events related to this study are to be reported to the 





Closed PIVC System without stabilization, available in 18-24 gauge; 




Open PIVC System without stabilization, available in 14-24 gauge, and has 




Closed PIVC System with built-in stabilization, available in 18-24 gauge, 
and has power injectable capability (with exception of 24 gauge), but has 




"Occupational exposure to blood borne pathogens related to leakage, spill, 
or splash of blood through needlesticks or cuts from other sharp instruments 
contaminated with an infected patient's blood or through contact of the eye, 






Blood leakage will be defined as blood leaking from the catheter onto an 
area unexpectedly.  For example, blood leaking onto intact skin, staff 
clothing, bed linen, or patient clothing would be considered blood leakage. 
 
Clinician Registered Nurse (RN), Licensed Practical Nurse (LPN), or Technician.  
Closed System 
Closed systems are PIVCs that may not require add ons during the insertion 
process.  The add ons and PIVC are one product, and come packaged as 
one unit together. 
 









According to the Sentara Healthcare (SHC) Incident and Event Reporting 
Risk Management Policy, any event unrelated to the ordinary course of the 
patient’s hospitalization, will be reported according to SHC policy.  
According to the policy, incident reporting is not a part of the medical 
record, and is not to contain information related to the hospitalization or 
treatment of any patient in the ordinary course of hospitalization of such 
patient.  Staff members with the best first-hand knowledge of what 
occurred should complete an incident and event report, according to policy 
and job aides.  Investigation will be initiated, as appropriate, within 24 






Profuse sweating, which may interfere with the adhesion of study PIVC 
dressings. 
 
Dwell time (E) 
The amount of time a catheter is dwelling in the vein (INS, 2016).  




Inadvertent administration of a nonvesicant solution or medication into 
surrounding tissue (INS, 2016).  Infiltration will be classified according to 
the INS, as follows: 0, no symptoms/signs; 1+, skin blanched, edema <1 
inch, cool to touch, with or without pain; 2+, skin blanched, edema 1-6 
inches, cool to touch, with or without pain; 3+, skin blanched/translucent, 
gross edema >6 inches, cold to touch, mild-moderate pain, possible 
numbness; and 4+, skin blanched, translucent, skin tight/leaking/discolored, 
bruised, swollen, gross edema >6 inches, deep pitting tissue edema, 
circulatory impairment, moderate-severe pain, infiltration of any amount of 









Informed consent is required for human subject participation in research 
according to federal rules and regulations (INS, 2016). 
N/A 
Inpatient 
Population (E)  
Inpatient is defined as an inpatient admission to an inpatient unit. Point of Entry 
Occlusion (E) 
The inability to flush the catheter without resistance and the inability to 





Open systems are PIVCs that require add ons to be added as part of the 
insertion process.  The add ons and PIVC are separate products, and do not 




Outpatient is defined as patients being treated in the Treatment Center, 
Cancer Center, ED, or designated as Observation Status.  
Point of Entry 












Standard Analog Scale 0-10 Scale or Wong Faces Scale  
Patient 
Identifiers (E) 





Satisfaction with the insertion process; evaluation of insertion and dwell 
time. 
 
Phlebitis (E)  
Mechanical causes of phlebitis result in vein wall irritation can be caused 
by multiple manipulations of infusion delivery system, large catheter gauge 
size, catheter material and diameter, failure to stabilize catheter adequately, 
failure to stabilize the joint if insertion site in or near a joint must be used.  
Signs and symptoms of phlebitis include pain/tenderness at site, erythema, 
warmth, swelling, induration, purulent drainage, palpable venous cord 
(INS, 2016).  Phlebitis will be classified according to the INS, as follows: 0, 
no symptoms/signs; 1+, redness with/without pain; 2+, redness and/or 
swelling accompanied with pain; and 3+, redness and/or swelling 
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Appendix C – Informed Consent 
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Appendix D – Patient & Clinician Demographics 
 
Table 2. Patient and Clinician Demographics 
Patient Demographics Clinician Demographics 
▪ Hospital Status (i.e. Outpatient vs. 
Inpatient) (E) 
▪ Working Area (Unit/Department) (P) 
▪ Age (E) ▪ Years of IV Insertion Experience (P) 
▪ MR# (E) ▪ IV Team Member - Yes/No? (P) 
▪ Encounter # (E) ▪ RN, LPN, Tech (P) 
▪ Gender (E)  
▪ Admitting Dx (E)  
▪ Principal Dx (E)  
▪ Secondary Dx's (E) (grouped by Dx 
categories) 
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Appendix E – Patient Questionnaire 
 
Completed after removal, up to a week to obtain 
 
PIVC Study – Patient Questionnaire 
Instructions:  After the study peripheral intravenous catheter (PIVC) is removed, please mark 
your evaluation of the study PIVC below.   
 
1.  While the PIVC was in place, what was your average pain level at the site of the PIVC? 
Circle the number on the scale where 0 is no pain and 10 is the worst pain you can imagine. 




         Severe 
Pain  
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Appendix F –Clinician Questionnaire (Front Side) 
 
PIVC Study – Clinician Questionnaire 
Completion of this questionnaire implies voluntary participation in the PIVC study and 
informed consent.  Your personal information will not be linked with this questionnaire. 
 
Insertion Date: ____________  Insertion Time:_________________ 
Insertion Facility:  ☐SRMH     ☐ SMJH     ☐SCH  
How many insertion attempts for success? 1 2 3 4 5 
 other:_______ 
How many staff attempted insertion?  1 2 3 
Did blood leak out of the catheter during or after insertion?  Yes No 
Blood leaked onto:☐ Patient ☐ Staff  ☐ Patient clothing  ☐ Staff clothing ☐ Bed Linen 
☐Other:____ 
Cleaning supplies used: ☐ Additional Gauze  ☐ Linen Towel  ☐Disinfectant wipe 
☐Other:____ 
Patient will go home with PIVC inserted:  ☐Yes    ☐ No 
What was the patient’s pain rating during insertion? 
Circle the number on the scale where 0 is no pain and 10 is the worst pain imaginable. 
0 1 2 3 4 5 6 7 8 9 10 
No 
Pain 
         Severe 
Pain 
Insertion Questions Disagree…………………………….Agree 
The flashback visualization was effective in assisting 
with insertion 
1 2 3 4 5 
Sharpness of needle is acceptable      
The catheter threads easily without kinking or bending      
The device is easy to use and does not affect my ability 
to start IV 
     
The needle safety feature operates reliably      
The use of this product requires you to use the needle 
safety feature 
     
The product stops the flow of blood after the needle is 
removed 
     
The user does not have to wipe blood from the patient’s 
skin surface surrounding IV site after insertion 
     
The user does not need extensive training for the 
product to be operated correctly 
     
Patient discomfort is not increased with use of this 
catheter 
     
Additional comments: 
         
Participant’s ID Code - Label 
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Appendix G –Clinician Training 
 
PIVC Study – Clinician Training 
Completion of this training implies voluntary participation in the PIVC study and 
informed consent.  Your personal information will not be linked with this questionnaire. 
 
Years of IV Insertion Experience:     
 < 1 year    1-3 years    3-6 years    6-10 years    > 10 years 
 
Please check the box next to your primary working unit:     
 ED    Treatment Center    Cancer Center    Inpatient Nursing Unit 
 
Are you a member of the IV Therapy Team?   Yes    No 
 
On a scale from 1 to 10, 1 being very low self-confidence with the skill of inserting 
PIVCs, and 10 being very high self-confidence with inserting PIVCs, where would you 
rate yourself today? (circle one) 
1 2 3 4 5 6 7 8 9 10 
Low self-confidence       High self-confidence 
 
Training Topics 




Reporting Adverse Events   
PIVC Insertion Policy   
Consent Process   
Inclusion / Exclusion Criteria   
PIVC Study Data Collection 
Instruments 
  
Onsite PIVC Training   
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RCT II Convenience Sample 
collected from 302 
medical-surgical 
patients from 9/2008-
12/2009, by VAD 









obtained, and written 
informed consent 





into the control 
group (receiving 




stabilization) or the 
investigational 
group (receiving 
the BD Nexiva 
Closed IV Catheter 












catheter – BD 






to the control catheter.  
Cox Regression Model 
HR 0.740 (90% CI: 
0.530-1.034) 
Reducing complications 





with the use of the 
investigational catheter 




Cox Regression Analysis 




complications by 26%, and 
was as effective, if not more 
so, in terms of location-
related complications, than 
the control catheter.  
Furthermore, Nurse 
satisfaction significantly 
increased with use of the 
investigational catheter.  
Findings support INS 
recommendation to use a 
catheter including a 
stabilization platform with 





et al, (2013) 
Prospective 
RCT 
II 952 catheters (513 
inpatients) - all 
patients ≥ 18 
receiving PIVC at 
PIVCs inserted and 
maintained in 
accordance with 
CDC guidelines.  
Compact closed 
System Catheter 
(COS) – BD Nexvia  
Results: 
Using COS PIVCs 
provides a RRR of 29% 
With use of the COS 
PIVCs, indwell times were 
significantly longer with 
phlebitis and infiltration 
Continued on next page 
 











Intervention Instruments Results/Stats Evidence Summary/ Conclusion 
one of three wards in 
Madrid, Spain 
between March and 
July 2008; target 
sample was 1200 
catheters to evaluate.   
 
126 nurses on the 
three wards 












and efficiency.  
Dwell time and 
complication rates 












of CRC compared to 
MOS PIVCs (CI 95%; 
p<0.001) 
 
MOS and COS PIVCs 
received no needle stick 
injuries during the study, 
proving that both are 
passive safety devices. 
 
Median time for indwell 
times before adverse 
event was significantly 
higher for COS group 
than the MOS group 
(P=0.003) 
 
Significant reduction in 
phlebitis rates of 29% 
(P=0.004) when using 
COS PIVCs. 
 
Total complications of 
COS PIVCs per 1000 
catheter-days (109.87) 
was significantly lower 
than the MOS PIVCs per 
rates being simultaneously, 
significantly lower.  While 
ease of use of the MOS 
PIVCs was of significance, 
attributed to nurses being 
familiar with the MOS 
system, less COS PIVCs 
needed to be removed due 
to CRC.  Overall total 
complications were less in 
the COS PIVCs group, than 
the MOS PIVCs group, 
indicating fewer 
complications from the 
closed catheter group versus 
the open catheter group. 
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analyzed using Chi 
Square or Fisher’s Exact 
Tests 
Quantitative Variables 









VI 104 nurses were 
recruited through 
telephone interviews 
and placed intone of 
two groups, based on 











nurses and nurse 
managers.  Nurses 
recruited were 










49% of nurse respondents 
using traditional SPIVCs 
indicated blood exposure 
50% of the time 
 
89% of nurse respondents 
using blood-contained 
SPIVCs indicated no 
blood exposure 89% of 
the time. 
Nurses that use blood-
contained SPIVC are less 
likely to experience blood 
exposures, if at all. 
Continued on next page 
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contained SPIVC 
(closed) groups and 
their telephone 








II 359-Patients ≥ 20 
years old, needing 
PIV for more than 72 





burns, lesions, or 
tattoos near the 
insertion site, patients 
receiving anticancer 
therapy, patients with 
limited insertion 









divided into two 
groups to receive 




to study month.  
i.e. patients 
enrolled in months 
1, 3, and 5 received 
the CICS; those 
enrolled in months 





trained in use of 
CICS and were 
required to 
successfully use the 
CICS in at least 
Catheters: 








observations and use 







Restart rates were 
significantly lower in the 
CICS group, than with the 
traditional catheter 
(open).   











Fisher’s Exact Test 
Kaplan-Meier Analysis 
 
There are no significant 
differences in incidence 
rates of adverse events 
between CICS and 
traditional catheters; 
however, restart rates are 
significantly lower in the 
CICS group.  CICS wing-
shaped stabilization 
platform was considered a 
contributing factor for the 
reason replacement rates 
were lower in the CICS 
group.   
 
This study supports using 
CICS to meet the CDC and 
INS recommendations. 
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Intervention Instruments Results/Stats Evidence Summary/ Conclusion 
five patients prior 
to start of the study. 
CDC= Centers for Disease Control; CI= Confidence Interval; CICS= closed intravenous catheter system; COS= Closed System; COSMOS= 
Closed System/Open System Study; CRC= Catheter-related Complications; ED= Emergency Room; HR= Hazard Ratio; INS= Infusion Nurses 
Society; MOS= Open System; OR= Operating Room; PIVC= Peripheral intravenous catheter; PIV= Peripheral intravenous catheter; PPS= per 
protocol set; RCT= Randomized Controlled Trial; RRR= Relative Risk Reduction; SPIVC= short traditional intravenous catheter; VAD= 
Venous Access device 
*Melnyk and Fineout-Overholt [3] used to determine level of evidence 
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